Patents by Inventor Kenneth Churchill Campbell

Kenneth Churchill Campbell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination and Uses and Treatments Thereof
    Publication number: 20240091159
    Abstract: Methods are provided for treating or preventing human immunodeficiency virus-1 (HIV-1) or human immunodeficiency virus-2 (HIV-2) in a virologically suppressed patient in need thereof comprising switching the patient from an antiretroviral treatment regimen comprising at least three antiretroviral agents to a treatment regimen comprising only two antiretroviral agents. In one aspect the two treatment regimen consists of dolutegravir, rilpivirine and at least one pharmaceutically acceptable excipient, diluent or carrier. In another aspect of the invention, there is provided a multilayer tablet comprising dolutegravir or a pharmaceutically acceptable salt thereof and rilpivirine or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 7, 2023
    Publication date: March 21, 2024
    Applicants: ViiV Healthcare Company, Janssen Sciences Ireland Unlimited Company
    Inventors: Kenneth Churchill CAMPBELL, Urbain Alfons C. DELAET, James M. GOODRICH, Juliette Segolène GUAQUIÈRE, Thomas LAUGHERY, Dominique J. LIMET, John C. POTTAGE, Ludovic Sylvain Marc RENOU, Trevor R. SCOTT, Christian SEILER, Mary WOODWARD
  • COMBINATION AND USES AND TREATMENTS THEREOF
    Publication number: 20200113838
    Abstract: Methods are provided for treating or preventing human immunodeficiency virus-1 (HIV-1) or human immunodeficiency virus-2 (HIV-2) in a virologically suppressed patient in need thereof comprising switching the patient from an antiretroviral treatment regimen comprising at least three antiretroviral agents to a treatment regimen comprising only two antiretroviral agents. In one aspect the two treatment regimen consists of dolutegravir, rilpivirine and at least one pharmaceutically acceptable excipient, diluent or carrier. In another aspect of the invention, there is provided a multilayer tablet comprising dolutegravir or a pharmaceutically acceptable salt thereof and rilpivirine or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: June 27, 2018
    Publication date: April 16, 2020
    Inventors: Kenneth Churchill CAMPBELL, Urbain Alfons C. DELAET, James M. GOODRICH, Juliette Segolène GUAQUIÈRE, Thomas LAUGHERY, Dominique J. LIMET, John C. POTTAGE, Ludovic Sylvain Marc RENOU, Trevor R. SCOTT, Christian SEILER, Mary WOODWARD
  • Famciclovir monohydrate
    Patent number: 7279483
    Abstract: Famciclovir monohydrate and its pharmaceutical use.
    Type: Grant
    Filed: November 3, 2004
    Date of Patent: October 9, 2007
    Assignee: Novartis AG
    Inventors: Kenneth Churchill Campbell, Michael John Greenway, Stephen Andrew Hancock
  • Activity of penciclovir against epstein-barr virus
    Publication number: 20030134864
    Abstract: Famciclovir monohydrate and its pharmaceutical use.
    Type: Application
    Filed: December 13, 2000
    Publication date: July 17, 2003
    Applicant: SmithKline Beecham p.l.c.
    Inventors: Kenneth Churchill Campbell, Michael John Greenway, Stephen Andrew Hancock